Can We Take Hyperuricemia as a Cardiovascular Risk?

IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
T. Ashraf, Raffat Sultana
{"title":"Can We Take Hyperuricemia as a Cardiovascular Risk?","authors":"T. Ashraf, Raffat Sultana","doi":"10.47144/phj.v56i1.2537","DOIUrl":null,"url":null,"abstract":"Study conducted for Gouty arthritis at Pan Pakistan level in 2017 showed mean Uric Acid levels of 6.11±1.7mg/dl with frequency of hyperuricemia of 39% and having 27.9% male and 49.35 women respectively.1\nThis type of arthritis results from monosodium urate crystal deposition in and around the joints affecting big toe around the joints of hands and feet. Gout has been shown to increase with age and associated with diabetes & hypertension.2,3 It has also been shown that hyperuricemia may be tied to increased risk of cardiovascular disease mortality.4\nHyperuricemia has also shown to increase atherosclerosis by   systemic inflammation and oxidative stress. It also causes endothelial dysfunction and oxidation of lipoproteins with formation of atherosclerotic plaques.5\nRecent studies have shown hypertension, coronary artery disease, cardiovascular diseases, vascular dementia and preclampsia to be associated with high uric acid levels. The studies include Rotterdam (Serum Uric Acid Level and Myocardial infraction),2 PUMA study (Serum Uric Acid levels with cardiovascular events and deaths in hypertensive patients),6 PAMELA study (increased risk of cardiovascular deaths with increase of every 1mg /dl).4\nThree important co-relation i.e. Hyperuricemia, atherosclerosis and heart failure need bit of understanding. In one study elevated uric acid levels (75.5mg/dl) in 90% of adolescents with essential hypertension7 and lower uric acid levels in teens with either white coat or secondary hypertension.7 Secondly association between increased uric acid levels and coronary artery calcification has shown an independent risk factor for subclinical atherosclerosis in young adults.8 Similar association was also seen in atherosclerotic vulnerable carotid plaque.9 Thirdly in cardiovascular health study incidence of heart failure was 21% with Chronic hyperuricemia and 18% without.10\nFor management of hyperuricemia (gout) multidisciplinary approach involving primary care physicians, rheumatologist and cardiologists might improve associated cardiovascular diseases other than primary pathology.\nDrugs like non-steroidal anti-inflammatory drug (NSAIDS), steroids & colchicine may improve Gout but improvement in cardiovascular comorbids are questionable.11,12\nThough different epidemiological studies have shown hyperuricemia as an independent risk factor for cardiovascular diseases and hypertension. Further studies are needed that my elucidate association of increased uric acid level with cardiovascular diseases. Multidisciplinary approach, awareness and counselling patient will hopefully prevent onset of heart disease and improve survival outcomes for gouty patients.\nReferences\n\nRaja S, Kumar A, Aahooja RD, Thakuria U, Ochani S, Shaukat F. Frequency of Hyperuricemia and its Risk Factors in the Adult Population. Cureus. 2019;11(3):e4198.\nGrassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-8.\nSattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):145-59.\nMuiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54-9.\nHayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab. 2004;1(1):1-5.\nShahin L, Patel KM, Heydari MK, Kesselman MM. Hyperuricemia and Cardiovascular Risk. Cureus. 2021;13(5):e14855.\nFeig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21.\nKrishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):1-8.\nLi Q, Zhou Y, Dong K, Wang A, Yang X, Zhang C, et al. The association between serum uric acid levels and the prevalence of vulnerable atherosclerotic carotid plaque: a cross-sectional study. Sci Rep. 2015;5(1):10003.\nKuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785-9.\nHansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021;3(1):e58-70.\nKajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y, Mutoh A, Ueda SI. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol. 2019;281:35-9.\n","PeriodicalId":42273,"journal":{"name":"Pakistan Heart Journal","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47144/phj.v56i1.2537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Study conducted for Gouty arthritis at Pan Pakistan level in 2017 showed mean Uric Acid levels of 6.11±1.7mg/dl with frequency of hyperuricemia of 39% and having 27.9% male and 49.35 women respectively.1 This type of arthritis results from monosodium urate crystal deposition in and around the joints affecting big toe around the joints of hands and feet. Gout has been shown to increase with age and associated with diabetes & hypertension.2,3 It has also been shown that hyperuricemia may be tied to increased risk of cardiovascular disease mortality.4 Hyperuricemia has also shown to increase atherosclerosis by   systemic inflammation and oxidative stress. It also causes endothelial dysfunction and oxidation of lipoproteins with formation of atherosclerotic plaques.5 Recent studies have shown hypertension, coronary artery disease, cardiovascular diseases, vascular dementia and preclampsia to be associated with high uric acid levels. The studies include Rotterdam (Serum Uric Acid Level and Myocardial infraction),2 PUMA study (Serum Uric Acid levels with cardiovascular events and deaths in hypertensive patients),6 PAMELA study (increased risk of cardiovascular deaths with increase of every 1mg /dl).4 Three important co-relation i.e. Hyperuricemia, atherosclerosis and heart failure need bit of understanding. In one study elevated uric acid levels (75.5mg/dl) in 90% of adolescents with essential hypertension7 and lower uric acid levels in teens with either white coat or secondary hypertension.7 Secondly association between increased uric acid levels and coronary artery calcification has shown an independent risk factor for subclinical atherosclerosis in young adults.8 Similar association was also seen in atherosclerotic vulnerable carotid plaque.9 Thirdly in cardiovascular health study incidence of heart failure was 21% with Chronic hyperuricemia and 18% without.10 For management of hyperuricemia (gout) multidisciplinary approach involving primary care physicians, rheumatologist and cardiologists might improve associated cardiovascular diseases other than primary pathology. Drugs like non-steroidal anti-inflammatory drug (NSAIDS), steroids & colchicine may improve Gout but improvement in cardiovascular comorbids are questionable.11,12 Though different epidemiological studies have shown hyperuricemia as an independent risk factor for cardiovascular diseases and hypertension. Further studies are needed that my elucidate association of increased uric acid level with cardiovascular diseases. Multidisciplinary approach, awareness and counselling patient will hopefully prevent onset of heart disease and improve survival outcomes for gouty patients. References Raja S, Kumar A, Aahooja RD, Thakuria U, Ochani S, Shaukat F. Frequency of Hyperuricemia and its Risk Factors in the Adult Population. Cureus. 2019;11(3):e4198. Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-8. Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):145-59. Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54-9. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab. 2004;1(1):1-5. Shahin L, Patel KM, Heydari MK, Kesselman MM. Hyperuricemia and Cardiovascular Risk. Cureus. 2021;13(5):e14855. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):1-8. Li Q, Zhou Y, Dong K, Wang A, Yang X, Zhang C, et al. The association between serum uric acid levels and the prevalence of vulnerable atherosclerotic carotid plaque: a cross-sectional study. Sci Rep. 2015;5(1):10003. Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K, et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014;37(8):785-9. Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021;3(1):e58-70. Kajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y, Mutoh A, Ueda SI. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol. 2019;281:35-9.
我们可以将高尿酸血症视为心血管风险吗?
2017年在Pan巴基斯坦进行的痛风性关节炎研究显示,平均尿酸水平为6.11±1.7mg/dl,高尿酸血症发生率为39%,男性占27.9%,女性占49.35%。这种类型的关节炎是由关节内和周围的尿酸钠晶体沉积引起的,影响手和脚关节周围的大脚趾。痛风已被证明随着年龄的增长而增加,并与糖尿病和高血压有关。2,3也有研究表明,高尿酸血症可能与心血管疾病死亡风险增加有关。高尿酸血症也通过全身炎症和氧化应激增加动脉粥样硬化。它还引起内皮功能障碍和脂蛋白氧化,形成动脉粥样硬化斑块。最近的研究表明,高血压、冠状动脉疾病、心血管疾病、血管性痴呆和先兆子痫与高尿酸水平有关。这些研究包括鹿特丹研究(血清尿酸水平和心肌梗死),2项PUMA研究(血清尿酸水平与高血压患者心血管事件和死亡的关系),6项PAMELA研究(每增加1mg /dl心血管死亡风险增加)。高尿酸血症、动脉粥样硬化和心力衰竭三个重要的相互关系需要了解。在一项研究中,90%患有原发性高血压的青少年尿酸水平升高(75.5mg/dl),而患有白大褂或继发性高血压的青少年尿酸水平较低其次,尿酸水平升高与冠状动脉钙化之间的关联已显示为年轻人亚临床动脉粥样硬化的独立危险因素类似的关联也见于动脉粥样硬化性颈动脉易损斑块第三,在心血管健康研究中,慢性高尿酸血症患者的心力衰竭发生率为21%,非慢性高尿酸血症患者为18%。对于高尿酸血症(痛风)的治疗,包括初级保健医生、风湿病学家和心脏病学家在内的多学科方法可能改善相关的心血管疾病,而不是原发性病理。非甾体抗炎药(NSAIDS)、类固醇和秋水仙碱等药物可能改善痛风,但对心血管合并症的改善尚存疑问。11,12尽管不同的流行病学研究表明高尿酸血症是心血管疾病和高血压的独立危险因素。尿酸水平升高与心血管疾病的关系有待进一步研究。多学科的方法,意识和咨询患者有望预防心脏病的发作和改善生存结果痛风患者。参考文献raja S, Kumar A, Aahooja RD, Thakuria U, Ochani S, Shaukat F.成人高尿酸血症发生率及其危险因素。Cureus。2019;11 (3):e4198。格拉西D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R,等。慢性高尿酸血症、尿酸沉积与心血管风险。中国医药杂志,2013;19(13):2432-8。痛风患者高尿酸血症的治疗:当前的治疗选择,最新发展和临床意义。中华肌肉骨骼杂志,2016;8(4):145-59。刘建军,刘建军,刘建军,等。尿酸与心血管疾病的关系研究进展。中华心血管病杂志,2016;11(1):54-9。Hayden MR, Tyagi SC.尿酸:对心血管疾病、代谢综合征和2型糖尿病的旧危险标志物的新认识:尿酸氧化还原穿梭。中华医学杂志,2004;1(1):1-5。王晓明,王晓明,王晓明。高尿酸血症与心血管疾病的关系。Cureus。2021;13 (5):e14855。李飞,姜德华,李荣杰。尿酸和心血管风险中华医学杂志,2008;32(3):391 - 391。Krishnan E, Pandya BJ, Chung L, Dabbous O.高尿酸血症与亚临床冠状动脉粥样硬化的风险——来自前瞻性观察队列研究的数据。中华关节炎杂志,2011;13(2):1-8。李强,周勇,董凯,王安,杨霞,张超,等。血清尿酸水平与易损动脉粥样硬化性颈动脉斑块患病率之间的关系:一项横断面研究。科学通报,2015;5(1):10003。Kuwabara M, Niwa K, Nishi Y, Mizuno A, Asano T, Masuda K,等。未接受高尿酸血症和高血压治疗的日本人血清尿酸水平与高血压的关系医学进展,2014;37(8):785-9。刘建军,刘建军,刘建军,等。风湿性关节炎与痛风的相关性研究。中华风湿病杂志,2013;3(1):558 -70。Kajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y, Mutoh A, Ueda SI。秋水仙碱短期治疗对冠心病患者内皮功能的影响。中华心血管病杂志,2019;28(1):39 - 39。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pakistan Heart Journal
Pakistan Heart Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
0.20
自引率
0.00%
发文量
64
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信